Glasgow Prognostic Score (GPS) Can Be a Useful Indicator to Determine Prognosis of Patients With Colorectal Carcinoma

Nozoe, Tetsuo; Matono, Rumi; Ijichi, Hideki; Ohga, Takefumi; Ezaki, Takahiro

doi:10.9738/intsurg-d-13-00118.1

Cited by 56 publications

(39 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, mGPS is 0 in the case of low albumin and low CRP (35). There are several studies, including recent meta-analysis, which indicate a clear association between high GPS and mGPS and poor OS and CSS irrespective of TNM stage and tumour differentiation (41)(42)(43)(44)7).…”

Section: Systemic Inflammation Markers In Crcmentioning

confidence: 99%

Systemic and local inflammation in colorectal cancer

Rumba¹,

Cipkina²,

Cukure³

et al. 2019

AML

View full text Add to dashboard Cite

Background. Colorectal cancer (CRC) is the third most common cancer in the world. The cornerstone of CRC treatment is surgical resection. However, patients in the same TNM stage show different recurrence rates and survival. Of patients with a local disease without lymph node or a distant metastasis, 20–25% still develop recurrence. There is evidence that inflammatory reaction is one of the key elements in tumour development. Materials and methods. We reviewed literature on colorectal cancer and its relationships with the immune system, with special focus on local and systemic inflammatory reaction. The Pubmed and ClinicalKey databases were searched using the key words colorectal cancer, local inflammation, systemic inflammation, markers of inflammation. The relevant literature was reviewed and included in the article. Results. The immune system has two-sided relationships with cancer, so it not only performs anti-tumour activities, but can also promote tumour growth and spread. Research has shown that signs of local inflammation are associated with a better prognosis in CRC. Systemic inflammation has been associated with more aggressive behaviour and a worse prognosis for patients with several cancers, including CRC. Conclusions. Recent findings in tumour biology have improved our understanding of colorectal cancer and of the natural course of this disease. Several markers of local and systemic inflammatory reaction have been identified. The next step is to find the most accurate and applicable marker, so that this promising tool can be used in clinical practice and aid in decision making.

show abstract

Section: Systemic Inflammation Markers In Crcmentioning

confidence: 99%

Systemic and local inflammation in colorectal cancer

Rumba¹,

Cipkina²,

Cukure³

et al. 2019

AML

View full text Add to dashboard Cite

show abstract

“…In chemo-naïve mCRC, Lin et al showed, using a sample size of 488 patients, that patients with high pre-chemotherapy LMR (≥3.11) experienced significant improvement in PFS (9.2 vs. 7.6 months, p < 0.001) and OS (19.4 vs. 16.6 months, p < 0.001) compared with patients with low pre-chemotherapy LMR. These results were also seen in the setting of resectable CRC, as a recent study published in March 2017 showed an independence of LMR in being a predictive factor of survival [ 59 ]. The study had a huge sample size of 1623 with a cut-off value of LMR 2.38.…”

Section: Literature Reviewmentioning

confidence: 75%

Inflammatory Markers and MicroRNAs: The Backstage Actors Influencing Prognosis in Colorectal Cancer Patients

Nasr

Hammoud

Nassar

et al. 2018

IJMS

View full text Add to dashboard Cite

Background: Colorectal cancer (CRC) remains a deadly disease, afflicting the lives of millions worldwide. The prognosis of CRC patients is best predicted by surgical resection and pathological analysis of specimens. Emerging evidence has attributed a significant role to inflammatory markers and microRNAs (miRNAs) in the prognosis and survival of CRC patients. Aim: Here, we review the literature on inflammatory markers and miRNAs with an established role on survival rates, response to systemic chemotherapy, and other clinic-pathological parameters in CRC patients. Results: Our literature review revealed a critical role of inflammatory markers—specifically, the acute-phase proteins, inflammatory cytokines, and blood cell ratios—on prognostic outcomes in CRC patients. MiRNAs, on the other hand, were useful in predicting prognosis and clinical response and accordingly stratifying CRC patients for optimal drug selection. Conclusion: These biomarkers are easily measured in routine blood exams and can be used in adjunct to the tumor-node-metastasis (TNM) staging system to identify high-risk patients and those who are more likely to benefit from chemotherapy and other targeted therapies. However, more prospective studies are needed for the validation of these discussed prognostic and predictive biomarkers.

show abstract

“…However, there is no consensus with regard to reduced SSI incidence or prolonged survival, and the effects of early introduction or co-administration with antitumor therapies, such as molecular targeted therapy, are anticipated in the future 23 . Cachexia was once regarded as an irreversible condition, but given that a reduction in the activity of inflammation-induced substances and suppression of inflammatory cytokine production could be achieved by initiating nutrition therapy before the patient falls into an intractable state of cachexia, active multimodal therapy may prove effective 24 .…”

Section: Discussionmentioning

confidence: 99%

Worse Preoperative Status Based on Inflammation and Host Immunity Is a Risk Factor for Surgical Site Infections in Colorectal Cancer Surgery

et al. 2017

View full text Add to dashboard Cite

Objective: The modified Glasgow Prognostic Score (mGPS) is an inflammation-based measure of malnutrition that reflects a state of cachexia in cancer patients. We evaluated mGPS as an index to predict surgical site infection (SSI) incidence in patients undergoing colorectal cancer surgery. Subjects and Methods:We retrospectively analyzed 351 patients who underwent colon cancer resection. Factors correlated with the incidence of SSIs were identified by logistic analysis and stepwise selection.Results: SSIs were observed in 32 patients, with an incidence of 9.1%. Univariate logistic analysis revealed mGPS (Score 2), laparotomy, resection of other organs, colostomy, excessive blood loss (>423 mL), long duration of surgery (>279 minutes), pulmonary dysfunction, prognostic nutritional index (PNI) ! 40, neutrophil lymphocyte ratio (NLR)(>4), and controlling nutritional status (CONUT) " 2 to be associated with an increased incidence of SSIs. Multivariate analysis with variables selected by the stepwise procedure also revealed mGPS (Score 2) (Odds ratio (OR)=3.55, 95% Confidence interval (CI) 1.30 9.56; p=0.01), colostomy (OR=6.56, 95%CI 1.60 31.38; p=0.01), excessive blood loss (OR=3.20, 95%CI1.23 8.42; p=0.02), and NLR (>4)(OR=3.24, 95%CI 1.31 8.17; p=0.01) to be independent risk factors.Conclusion: mGPS is an independent risk factor for SSIs. Our results suggest that cachexia before surgery in patients with colorectal cancer might predict the incidence of SSIs. (J Nippon Med Sch 2017; 84: 224 230)

show abstract

Glasgow Prognostic Score (GPS) Can Be a Useful Indicator to Determine Prognosis of Patients With Colorectal Carcinoma

Cited by 56 publications

References 23 publications

Systemic and local inflammation in colorectal cancer

Systemic and local inflammation in colorectal cancer

Inflammatory Markers and MicroRNAs: The Backstage Actors Influencing Prognosis in Colorectal Cancer Patients

Worse Preoperative Status Based on Inflammation and Host Immunity Is a Risk Factor for Surgical Site Infections in Colorectal Cancer Surgery

Contact Info

Product

Resources

About